Neurology · Chicago area, IL
Neurology studies in Chicago area, IL
74 recruiting studies have a site in the Chicago area. This page includes nearby cities such as Evanston, Oak Brook, Oak Lawn, Park Ridge.
74 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersEarly Phase 1
Effect of Neural Constraints on Movement in Stroke
Northwestern University
- Location
- Chicago, IL
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersEarly Phase 1
R01.Aim 2.Study 1: IsoReach
Shirley Ryan AbilityLab
- Location
- Chicago, IL
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteers
Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device
Neurogen Biomarking LLC
- Location
- Chicago, IL
- Eligibility basics
- Ages 40–90
- RecruitingHealthy volunteers
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment…
GAP Innovations, PBC
- Location
- Chicago, IL + 18 other US sites
- Eligibility basics
- Ages 60–90
- RecruitingHealthy volunteersPhase 3
Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease
CereMark Pharma, LLC
- Location
- Evanston, IL
- Eligibility basics
- Ages 45+
- RecruitingHealthy volunteers
Feasibility of Using the Gatorade Sports Science Institute (GSSI) Labs App for Hydration Related Outcomes
PepsiCo Global R&D
- Location
- Chicago, IL
- Eligibility basics
- Ages 18–65
- RecruitingPhase 1/Phase 2
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
Encoded Therapeutics
- Location
- Chicago, IL + 9 other US sites
- Eligibility basics
- Ages 6 mo–17
- RecruitingPhase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
TG Therapeutics, Inc.
- Location
- Chicago, IL + 35 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2/Phase 3
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
Biohaven Therapeutics Ltd.
- Location
- Chicago, IL + 24 other US sites
- Eligibility basics
- Ages 40–80
- Recruiting
Thrombectomy Using Pulsed Aspiration for Reperfusion of Brain Occlusions
RapidPulse, Inc
- Location
- Chicago, IL + 12 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 3
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Sanofi
- Location
- Glenview, IL + 31 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Hoffmann-La Roche
- Location
- Chicago, IL + 67 other US sites
- Eligibility basics
- Ages 50–90
- RecruitingPhase 3
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
Kallyope Inc.
- Location
- Chicago, IL + 111 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated
- Location
- Chicago, IL + 57 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
Rapport Therapeutics Inc.
- Location
- Chicago, IL + 12 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
Kallyope Inc.
- Location
- Gurnee, IL + 35 other US sites
- Eligibility basics
- Ages 18–75
- Recruiting
The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms
phenox Inc.
- Location
- Chicago, IL + 24 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Novartis Pharmaceuticals
- Location
- Chicago, IL + 42 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome
Epygenix
- Location
- Chicago, IL + 16 other US sites
- Eligibility basics
- Ages 2–55
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
Dianthus Therapeutics
- Location
- Chicago, IL + 29 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Bristol-Myers Squibb
- Location
- Chicago, IL + 22 other US sites
- Eligibility basics
- Ages 60–85
- RecruitingPhase 3
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
Alnylam Pharmaceuticals
- Location
- Chicago, IL + 9 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Bristol-Myers Squibb
- Location
- Chicago, IL + 23 other US sites
- Eligibility basics
- Ages 60–85
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Hoffmann-La Roche
- Location
- Chicago, IL + 52 other US sites
- Eligibility basics
- Ages 50–85
Who these studies look for
Most require a confirmed diagnosis; memory studies often ask for a study partner who knows you well to attend some visits.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.